The solution to the breakthrough therapies program's overwhelming workload was not creating a new user fee or new requirements, but strengthening FDA's review divisions.
More than 15% of the expected new full-time equivalents that will come from the prescription drug user fee reauthorization will be rank-and-file reviewers and related staff targeted at
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?